Raltegravir Once Daily versus Twice Daily

QDMRK Trial
Raltegravir Once Daily versus Twice Daily in Combination Therapy

QDMRK: Study Design

Study Design: QDMRK Study

• **Background:** Randomized, double-blind, phase 3 trial in antiretroviral-naïve subjects to compare the efficacy of once-daily with twice-daily raltegravir

• **Inclusion Criteria (n = 775)**
  - Age ≥18 years
  - Antiretroviral-naïve
  - HIV RNA >5,000 copies/mL
  - No CD4 criteria
  - No relevant mutations

• **Treatment Arms**
  - Raltegravir 800 mg QD + TDF-FTC
  - Raltegravir 400 mg BID + TDF-FTC

Raltegravir Once Daily versus Twice Daily in Combination Therapy

QDMRK: Results

Virologic Response: Week 48 (non-completer = failure)

Interpretation: “Despite high response rates with both regimens, once-daily raltegravir cannot be recommended in place of twice-daily dosing.”
Acknowledgment

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.